A Multi-Center, Randomized, Sham-Controlled, Phase II Trial Evaluating Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair (The PREVENT-PVR Trial)
Latest Information Update: 07 May 2024
At a glance
- Drugs Aflibercept (Primary)
- Indications Proliferative vitreoretinopathy; Retinal detachment
- Focus Therapeutic Use
- Acronyms PREVENT-PVR
- 02 May 2022 Planned End Date changed from 15 Sep 2021 to 15 Dec 2023.
- 02 May 2022 Planned primary completion date changed from 15 Sep 2021 to 15 Sep 2023.
- 09 Oct 2020 New trial record